These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26162576)

  • 1. Feasibility of measuring renal blood flow by phase-contrast magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease.
    Spithoven EM; Meijer E; Borns C; Boertien WE; Gaillard CA; Kappert P; Greuter MJ; van der Jagt E; Vart P; de Jong PE; Gansevoort RT
    Eur Radiol; 2016 Mar; 26(3):683-92. PubMed ID: 26162576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease.
    King BF; Torres VE; Brummer ME; Chapman AB; Bae KT; Glockner JF; Arya K; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Dec; 64(6):2214-21. PubMed ID: 14633145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE; King BF; Chapman AB; Brummer ME; Bae KT; Glockner JF; Arya K; Risk D; Felmlee JP; Grantham JJ; Guay-Woodford LM; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):112-20. PubMed ID: 17699395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.
    Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM
    Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
    Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
    J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciné phase-contrast magnetic resonance imaging for the measurement of renal blood flow.
    Prowle JR; Molan MP; Hornsey E; Bellomo R
    Contrib Nephrol; 2010; 165():329-336. PubMed ID: 20427985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal renal blood flow measurement using phase-contrast cine magnetic resonance imaging.
    Sommer G; Noorbehesht B; Pelc N; Jamison R; Pinevich AJ; Newton L; Myers B
    Invest Radiol; 1992 Jun; 27(6):465-70. PubMed ID: 1607260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging 3T and total fibrotic volume in autosomal dominant polycystic kidney disease.
    Lai S; Mastroluca D; Letizia C; Petramala L; Perrotta AM; DiGaeta A; Ferrigno L; Ciccariello M; D'Angelo AR; Panebianco V
    Intern Med J; 2018 Dec; 48(12):1505-1513. PubMed ID: 30043487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy.
    Mora-Gutiérrez JM; Garcia-Fernandez N; Slon Roblero MF; Páramo JA; Escalada FJ; Wang DJ; Benito A; Fernández-Seara MA
    J Magn Reson Imaging; 2017 Dec; 46(6):1810-1817. PubMed ID: 28383796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney Function Reserve Capacity in Early and Later Stage Autosomal Dominant Polycystic Kidney Disease.
    Messchendorp AL; van Londen M; Taylor JM; de Borst MH; Navis G; Casteleijn NF; Gaillard CAJM; Bakker SJL; Gansevoort RT;
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1680-1692. PubMed ID: 30254028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of arterial transit time and renal blood flow using pseudocontinuous ASL MRI with multiple post-labeling delays: Feasibility, reproducibility, and variation.
    Kim DW; Shim WH; Yoon SK; Oh JY; Kim JK; Jung H; Matsuda T; Kim D
    J Magn Reson Imaging; 2017 Sep; 46(3):813-819. PubMed ID: 28092411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
    Zand L; Torres VE; Larson TS; King BF; Sethi S; Bergstralh EJ; Angioi A; Fervenza FC
    Nephrol Dial Transplant; 2016 Aug; 31(8):1290-5. PubMed ID: 26614268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current diagnostic evaluation of autosomal dominant polycystic kidney disease.
    Wołyniec W; Jankowska MM; Król E; Czarniak P; Rutkowski B
    Pol Arch Med Wewn; 2008 Dec; 118(12):767-73. PubMed ID: 19202957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autosomal dominant polycystic kidney disease: new role for ultrasound.
    İmamoğlu H; Zararsız G; Doğan S; Koçyiğit İ; Eroğlu E; Öztürk A; Erdoğan N
    Eur Radiol; 2019 Nov; 29(11):5991-5998. PubMed ID: 31028448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M; Inci A
    Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.